Business Description
InMed Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA4576371062
Description
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.28 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -14.85 | |||||
| Beneish M-Score | -1.92 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 70.1 | |||||
| 3-Year EPS without NRI Growth Rate | 70.3 | |||||
| 3-Year FCF Growth Rate | 71 | |||||
| 3-Year Book Growth Rate | -64.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.79 | |||||
| 9-Day RSI | 47.11 | |||||
| 14-Day RSI | 47.72 | |||||
| 6-1 Month Momentum % | -16.4 | |||||
| 12-1 Month Momentum % | -36.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.07 | |||||
| Quick Ratio | 4.22 | |||||
| Cash Ratio | 3.89 | |||||
| Days Inventory | 119.25 | |||||
| Days Sales Outstanding | 20.38 | |||||
| Days Payable | 46.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -202.6 | |||||
| Shareholder Yield % | -187.56 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 31.69 | |||||
| Operating Margin % | -146.42 | |||||
| Net Margin % | -137.41 | |||||
| FCF Margin % | -133.8 | |||||
| ROE % | -66.76 | |||||
| ROA % | -55.14 | |||||
| ROIC % | -171.18 | |||||
| ROC (Joel Greenblatt) % | -364.7 | |||||
| ROCE % | -67.43 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.1 | |||||
| PB Ratio | 0.37 | |||||
| Price-to-Tangible-Book | 0.47 | |||||
| EV-to-EBIT | 0.19 | |||||
| EV-to-EBITDA | 0.21 | |||||
| EV-to-Revenue | -0.28 | |||||
| EV-to-Forward-Revenue | 0.01 | |||||
| EV-to-FCF | 0.21 | |||||
| Price-to-Net-Current-Asset-Value | 0.6 | |||||
| Price-to-Net-Cash | 0.88 | |||||
| Earnings Yield (Greenblatt) % | 526.32 | |||||
| FCF Yield % | -197.5 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
InMed Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4.961 | ||
| EPS (TTM) ($) | -65.4 | ||
| Beta | 0.37 | ||
| Volatility % | 127.17 | ||
| 14-Day RSI | 47.72 | ||
| 14-Day ATR ($) | 0.448965 | ||
| 20-Day SMA ($) | 4.78453 | ||
| 12-1 Month Momentum % | -36.55 | ||
| 52-Week Range ($) | 2.414 - 15.696 | ||
| Shares Outstanding (Mil) | 0.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
InMed Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
InMed Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
InMed Pharmaceuticals Inc Frequently Asked Questions
What is InMed Pharmaceuticals Inc(INM)'s stock price today?
The current price of INM is $4.66. The 52 week high of INM is $15.70 and 52 week low is $2.41.
When is next earnings date of InMed Pharmaceuticals Inc(INM)?
The next earnings date of InMed Pharmaceuticals Inc(INM) is 2025-02-13 Est..
Does InMed Pharmaceuticals Inc(INM) pay dividends? If so, how much?
InMed Pharmaceuticals Inc(INM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers